Original Contribution | Published:

Stomach

Helicobacter pylori Eradication: A Randomized Prospective Study of Triple Therapy Versus Triple Therapy Plus Lactoferrin and Probiotics

The American Journal of Gastroenterology volume 102, pages 951956 (2007) | Download Citation

Subjects

Abstract

OBJECTIVES:

Helicobacter pylori is causally associated with gastritis and peptic ulcer diseases. Recent data (meta-analysis) have demonstrated that triple therapy with amoxicillin, clarithromycin, and a proton pump inhibitor has an eradication rate of only 74–76% and new therapeutic protocols may be necessary. The aim of this study was to examine whether adding bovine lactoferrin (bLf) and probiotics (Pbs) to the standard triple therapy for H. pylori infection could improve the eradication rate and reduce side effects.

METHODS:

H. pylori infection was diagnosed in 206 patients: in 107 based on an upper endoscopy exam and a rapid urease test, and in 99 by means of the H. pylori stool antigen-test and the C13 urea breath test (C13 UBT). The patients were randomized into two groups: 101 patients (group A) underwent standard triple eradication therapy (esomeprazole, clarithromycin, amoxicillin), while 105 patients (group B) underwent a modified eradication therapy (standard triple eradication therapy plus bLf and Pb). Successful eradication therapy was defined as a negative C13 UBT 8 wk after completion of the treatment. Results were evaluated by intention-to-treat (ITT) and per-protocol (PP) analysis. Data were evaluated and considered positive when P < 0.05.

RESULTS:

At the end of the study 175/206 patients showed negative C13 UBT results. According to intention-to-treat analysis, the infection was eradicated in 73/101 patients from Group A and in 93/105 from Group B. PP analysis showed 73/96 patients from Group A and 93/101 from Group B to have been successfully treated. More patients from group A than from group B reported side effects from their treatment (P < 0.05).

CONCLUSIONS:

The results of our study suggest that the addition of bLf and Pbs could improve the standard eradication therapy for H. pylori infection—bLf serving to increase the eradication rate and Pbs to reduce the side effects of antibiotic therapy.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , , et al. European Helicobacter pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection—The Maastricht 2-2000 Consensus report. Aliment Pharmacol Ther 2002;16:167–180.

  2. 2.

    , , , et al. Meta-analysis: Comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2003;18:647–654.

  3. 3.

    . Eradication of Helicobacter pylori infection. Am J Med 1996;100:42S–51S.

  4. 4.

    , , . Bactericidal activities of human lactoferrin: Sensitivity of a variety of microrganisms. Infect Immun 1980;28:893–898.

  5. 5.

    , , , et al. Identification of the bactericidal domain of lactoferrin. Biochem Biophys Acta 1992;1121:130–136.

  6. 6.

    , . Probiotics and non-intestinal infectious conditions. Br J Nutr 2002;88(suppl 1):ss59–66.

  7. 7.

    , , , et al. Effects of a specially designed fermented milk product containing probiotic Lactobacillus casei DN-114 001 and the eradication of H. pylori in children: A prospective randomized double-blind study. J Clin Gastroenterol 2005;39:692–698.

  8. 8.

    , , , et al. Probiotics reduce bacterial colonization and gastric inflammation in H. pylori-infected mice. Dig Dis Sci 2004;49:1095–1102.

  9. 9.

    , , , et al. In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota. Appl Environ Microbiol 2004;70:518–526.

  10. 10.

    , . Probiotics and Helicobacter pylori. Best Pract Res Clin Gastroenterol 2003;17:785–791.

  11. 11.

    , , , et al. Ranitidine bismuth citrate-based triple therapy for seven days, with or without further anti-secretory therapy, is highly effective in patients with duodenal ulcer and Helicobacter pylori infection. Eur J Gastroenterol Hepatol 2001;13:547–550.

  12. 12.

    , , , et al. One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease. Eur J Gastroenterol Hepatol 2001;13:1457–1465.

  13. 13.

    , , , et al. Therapy of Helicobacter pylori. Helicobacter 2004;9(suppl 1):42–48.

  14. 14.

    , , , et al. Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori. World J Gastroenterol 2004;10:1656–1658.

  15. 15.

    , . Primary and secondary resistance to Helicobacter pylori strain isolated in central Italy during the years 1998–2002. Dig Liver Dis 2003;35:541–545.

  16. 16.

    , , , et al. Impact of Helicobacter pylori resistance to clarithromycin on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy. Aliment Pharmacol Ther 2001;15:707–713.

  17. 17.

    , , , et al. Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis 2000;19:538–541.

  18. 18.

    , , , et al. Antibiotic properties of bovine lactoferrin on Helicobacter pylori. Dig Dis Sci 1998;43:2750–2756.

  19. 19.

    . Lactoferrin in human milk: Its role in iron absorption and protection against enteric infection in the newborn infant. Arch Dis Child 1980;55:417–421.

  20. 20.

    , , , et al. Bacterial lactoferrin receptors. Adv Exp Med Biol 1998;443:123–133.

  21. 21.

    , . Lactoferrin: A general review. Haematologica 1995;80:252–267.

  22. 22.

    , , . A bactericidal effect for human lactoferrin. Science 1977;197:263–265.

  23. 23.

    , , , et al. Antibacterial activity of lactoferrin and a pepsin-derived lactoferrin peptide fragment. Infect Immun 1993;61:719–728.

  24. 24.

    , , , et al. Relationship between antibacterial activity and porin binding of lactoferrin in Escherichia coli and Salmonella typhimurium. Antimicrob Agents Chemother 1993;37:240–245.

  25. 25.

    , , , et al. The therapeutic effect of bovine lactoferrin in the host infected with Helicobacter pylori. Scand J Gastroenterol 1999;34:238–243.

  26. 26.

    . Lactoferrin: A multifunctional immunoregulatory protein? Immunol Today 1995;16:417–419.

  27. 27.

    , , , et al. Lactoferricin, a new antimicrobial peptide. J Appl Bacteriol 1994;77:208–214.

  28. 28.

    , , , et al. Use of bovine lactoferrin for Helicobacter pylori eradication. Dig Liver Dis 2003;35:706–710.

  29. 29.

    , , , et al. Bovine lactoferrin for Helicobacter pylori eradication: An open, randomized, multicentre study. Aliment Pharmacol Ther 2006;23:1235–1240.

  30. 30.

    , , . Biotherapeutic agent. A neglected modality for the treatment and prevention of selected intestinal and vaginal infection. J Am Med Assoc 1996;275:870–876.

  31. 31.

    , , , et al. A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. Aliment Pharmacol Ther 2000;14:1625–1629.

  32. 32.

    , , , et al. Impact of supplement with Lactobacillus- and Bifidobacterium-containing yoghurt on triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2002;6:1669–1675.

  33. 33.

    , , , et al. Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans. Digestion 1999;60:203–209.

  34. 34.

    , . Probiotics and non-intestinal infectious conditions. Br J Nutr 2002;88(suppl 1):S59–S66.

  35. 35.

    , , . Effect of probiotics on the prevention of diarrhea in Helicobacter pylori therapy. Nippon Rinsho 2005;63(suppl 11):539–542.

  36. 36.

    , , , et al. Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy—a placebo-controlled, double-blind randomized pilot study. Aliment Pharmacol Ther 2005;21:1263–1272.

  37. 37.

    , , , et al. The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2001;15:163–169.

  38. 38.

    , , , et al. Effect of a probiotic formula on intestinal immunoglobulin A production in healthy children. Int J Food Microbiol 1998;42:39–44.

  39. 39.

    , , , et al. Quadruple therapy with lactoferrin for Helicobacter pylori eradication: A randomised, multicentre study. Dig Liver Dis 2005;37:496–500.

  40. 40.

    , , , et al. Recombinant human lactoferrin is effective in the treatment of Helicobacter felis-infected mice. J Pharm Pharmacol 2000;52:1541–1546.

Download references

Author information

Affiliations

  1. Gastroenterology Unit, Department of Medical and Surgical Gastroenterology, University of Pisa, Pisa, Italy

    • Nicola de Bortoli
    • , Giulia Leonardi
    • , Andrea Merlo
    • , Massimo Bellini
    • , Francesco Costa
    • , Maria Gloria Mumolo
    • , Angelo Ricchiuti
    • , Fabrizio Cristiani
    •  & Santino Marchi
  2. Surgery Unit IV, Department of Medical and Surgical Gastroenterology, A.U.O. Pisa, Pisa, Italy

    • Stefano Santi
    •  & Mauro Rossi
  3. Pathological Anatomy Unit II, Department of Oncology, Transplantation and New Technology in Medicine, A.U.O. Pisa, Pisa, Italy

    • Eugenio Ciancia

Authors

  1. Search for Nicola de Bortoli in:

  2. Search for Giulia Leonardi in:

  3. Search for Eugenio Ciancia in:

  4. Search for Andrea Merlo in:

  5. Search for Massimo Bellini in:

  6. Search for Francesco Costa in:

  7. Search for Maria Gloria Mumolo in:

  8. Search for Angelo Ricchiuti in:

  9. Search for Fabrizio Cristiani in:

  10. Search for Stefano Santi in:

  11. Search for Mauro Rossi in:

  12. Search for Santino Marchi in:

Corresponding author

Correspondence to Nicola de Bortoli.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1111/j.1572-0241.2007.01085.x

Further reading